Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 6 institutions in 2 countries.
Selvi C ErsoyThe Lundquist Institute for Biomedical Innovations at Harbor-UCLA Medical Center, Torrance, California, USA.ORCID 0000-0002-8792-2061
Richard A ProctorDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Warren E RoseSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-5012-5993
Wessam AbdelhadyThe Lundquist Institute for Biomedical Innovations at Harbor-UCLA Medical Center, Torrance, California, USA.
Sook-Ha FanThe Lundquist Institute for Biomedical Innovations at Harbor-UCLA Medical Center, Torrance, California, USA.ORCID 0000-0003-0556-238X
Sabrina L MadrigalCalifornia State University-Los Angeles, Los Angeles, California, USA.
Ahmed M ElsayedThe Lundquist Institute for Biomedical Innovations at Harbor-UCLA Medical Center, Torrance, California, USA.
Henry F ChambersUniversity of California-San Francisco School of Medicine, San Francisco, California, USA.
Rita G SobralLaboratory of Molecular Microbiology of Bacterial Pathogens, UCIBIO, Applied Molecular Biosciences Unit, Department of Life Sciences, Nova School of Science and Technology, Universidade Nova de Lisboa, Caparica, Portugal.ORCID 0000-0003-4533-7531
Arnold S BayerThe Lundquist Institute for Biomedical Innovations at Harbor-UCLA Medical Center, Torrance, California, USA.
UCLA Medical Center · USUniversity of Wisconsin–Madison · USCalifornia State University Los Angeles · USUniversidade Nova de Lisboa · PTUniversity of California, Los Angeles · USUniversity of California, San Francisco · US
Funding
Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical TranslatabilityR01AI146078 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI XIONG, YAN Q. · 2019 to 2023
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Sensitizing methicillin-resistant · full record | OpenQuestion